Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE recommends more digital mental health therapies for NHS use

March 1, 2023
Medical Communications

Eight more digital therapies (DTx) for mental health disorders have been recommended by NICE for use by the NHS, following …

News

FDA approves Reata Pharmaceuticals’ first-in-class treatment for Friedreich’s Ataxia

March 1, 2023
Medical Communications

US-based Reata Pharmaceuticals has announced that its first-in-class treatment for Friedreich’s Ataxia (FA), Skyclarys, has been given FDA approval. This …

News

BioNxt Solutions signs clinical study agreement and commences clinical samples manufacture for Parkinson’s disease trial

March 1, 2023
Research and Development

BioNxt Solutions, a bioscience accelerator focused on next-generation drug formulations and delivery systems, has announced the finalisation of its comparative …

News

Sequana Medical shares positive results from phase 1 clinical trial

March 1, 2023
Research and Development

Sequana Medical has shared positive results from its phase 1 trial, CHIHUAHUA, assessing the safety and tolerability of a single …

News

Industrywide Survey Reveals Centralising Regulatory is Number One Priority for Medtech

March 1, 2023
Business Services

BARCELONA, Spain — 28 Feb. 2023 — New research shows a majority of medtech organizations are taking action to advance …

News
Press release

Ascelia Pharma meets major milestone with patient enrollment completion of Phase 3 Study for Orviglance, novel MRI contrast agent for patients with kidney impairment

February 28, 2023
Business Services

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, …

News
Press release

Johnson & Johnson’s Janssen-Cilag unit gets disappointing ‘restricted’ label for PARP drug in EU

February 28, 2023
Medical Communications

Johnson & Johnson (J&J)’s Janssen-Cilag unit has announced that its fixed-dose combination drug Akeega has been recommended for approval by …

News

Moderna to pay $400m to US government over new COVID-19 vaccine license

February 28, 2023
Sales and Marketing

Moderna, a leader in the development of COVID-19 vaccines, announced that it has paid the National Institute of Allergy and …

News

CSL receives positive results from rare disease drug phase 3 trial

February 28, 2023
Research and Development

Biotech company CSL has reported positive results from its phase 3 trial for garadacimab, a monthly treatment for hereditary angioedema …

News

MHRA’s authority restored following Northern Ireland Brexit deal

February 28, 2023
Medical Communications

The Medicines and Healthcare products Regulatory Agency (MHRA) has been limited to approving medicines in Great Britain (England, Scotland and …

News

Rare and orphan disease expert Terebellum launches market access guide

February 28, 2023
Business Services

Terebellum, subsidiary of global specialty pharmacy and healthcare solutions organisation AscellaHealth, is launching a strategic guide to help manufacturers bring …

News
Press release

Rare disease community call for their unified voice to be heard in the fight for equitable care

February 28, 2023
Business Services

Reading, 28th February 2023.

News
Press release

PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)

February 27, 2023
Business Services

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, noted today that its Founded …

News
Press release

Almirall opens the doors of its R&D centre to the biotech ZeClinics

February 27, 2023
Business Services

BARCELONA, Spain. February 27th 2023 – Almirall, a global biopharmaceutical company focused on skin health, today announced an agreement with …

News
Press release

HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China

February 27, 2023
Business Services

Hong Kong, Shanghai & Florham Park, NJ — Monday, February 27, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces …

News
Press release

CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System

February 27, 2023
Business Services

Cambridge, UK, 27 February 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems …

News
Press release

Five Alarm Bio, Focused on Minimising the Effects of Aging in Humans, Raises Seed Investment

February 27, 2023
Business Services

Cambridge, UK, 27 February 2023: Five Alarm Bio (FAB), a drug discovery company focused on novel approaches to anti-aging, announced …

News
Press release

FDA sued by US states over abortion pill access

February 27, 2023
Medical Communications

Attorneys general (AGs) from 12 Democrat-led US states have made complaints to the FDA in an attempt to force the …

News

Causeway Therapeutics raises £8.75m for tennis elbow research

February 27, 2023
Medical Communications

University of Glasgow spin-out Causeway Therapeutics has announced that it has raised £8.75m from investors, which will fund an international …

News

AbbVie gains positive CHMP opinion for upadacitinib for the treatment of Crohn’s disease

February 27, 2023
Medical Communications

AbbVie has announced that it has received positive feedback from the EMA’s Committee for Medicinal Products for Human Use (CHMP) …

News
The Gateway to Local Adoption Series

Latest content

Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation

January 22, 2026

PSI appoints David Allen as Country Manager for Canada

January 22, 2026

Qureight appoints Steven Bishop as Chief Medical Officer

January 21, 2026

Pierre Fabre Laboratories and Iktos announce oncology collaboration

January 21, 2026

Qureight appoints Rebecca Simmons as Chief Operating Officer

January 20, 2026